Sarepta Therapeutics to Present Company Overview at the 32nd Canaccord Genuity Annual Growth Conference
Webcast Accessible via Sarepta Therapeutics Website
(firmenpresse) - CAMBRIDGE, MA -- (Marketwire) -- 08/01/12 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 32nd Canaccord Genuity Annual Growth Conference in Boston, MA on Wednesday, August 15, 2012 at 4:30 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarepta Therapeutics' website at and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at .
Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2012 - 20:05 Uhr
Sprache: Deutsch
News-ID 170913
Anzahl Zeichen: 0
contact information:
Town:
CAMBRIDGE, MA
Kategorie:
Trials
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sarepta Therapeutics to Present Company Overview at the 32nd Canaccord Genuity Annual Growth Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Sarepta Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
